Login to Your Account

FDA workload demands lead to adjustments in Rx and biosimilar fees

By Mari Serebrov
Regulatory Editor

Thursday, September 14, 2017

Reflecting a record-high workload at the FDA's drug center, the reconstructed PDUFA fees for fiscal 2018 will have to generate more than $911 million in revenue over the next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription